Enclomiphene Citrate Overdose and Accidental Excess Dose: Recognition, Risks, and Clinical Management

How Enclomiphene Citrate Works and Why Dose Matters

Enclomiphene citrate is the pharmacologically active trans-isomer of clomiphene citrate, classified as a selective estrogen receptor modulator (SERM). It competitively blocks estrogen receptors in the hypothalamus, removing negative feedback and triggering increased pulsatile release of gonadotropin-releasing hormone (GnRH). This raises both luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulates testicular testosterone production while preserving spermatogenesis.

Kim et al. demonstrated in a controlled study (N=48) that enclomiphene at 12.5 and 25 mg daily restored serum testosterone to eugonadal levels in men with secondary hypogonadism while maintaining sperm parameters 1. That trial anchors the therapeutic window most compounding pharmacies follow today. Understanding this mechanism is directly relevant to overdose because the drug's effects are dose-dependent: higher doses produce greater hypothalamic estrogen receptor blockade, more aggressive gonadotropin release, and amplified downstream hormonal shifts.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy notes that SERMs like clomiphene citrate can raise testosterone levels by 200 to 300% from baseline at standard doses 2. Exceeding the intended dose could push this response further, though the ceiling effect of receptor saturation provides some pharmacologic protection against runaway stimulation.

What Constitutes an Overdose of Enclomiphene Citrate

An overdose is any single intake or cumulative daily intake that exceeds the prescribed dose. That definition is simple. The clinical reality is more nuanced.

For men using compounded enclomiphene for secondary hypogonadism, typical prescribed doses range from 12.5 to 25 mg per day. An accidental double dose (taking 25 mg twice, for example) brings the total to 50 mg, which is still within the dose range studied for clomiphene citrate in male fertility protocols. The FDA-approved labeling for clomiphene citrate (Clomid) in female ovulation induction permits doses up to 100 mg daily for five days, and doses of 150 mg daily have been used off-label 3.

This context matters. A single accidental excess dose of enclomiphene in the 25 to 50 mg range carries a very different risk profile than sustained supratherapeutic dosing over weeks. The former is unlikely to produce anything beyond transient side effects. The latter may drive estradiol suppression, visual toxicity, or mood disturbance that requires clinical intervention.

No published case report documents a life-threatening or fatal overdose of either enclomiphene or racemic clomiphene citrate in any patient population 4.

Expected Symptoms After an Accidental Excess Dose

The symptom profile after excessive enclomiphene intake mirrors the known adverse-effect spectrum of clomiphene citrate, amplified by dose. Gastrointestinal symptoms typically appear first. Visual changes are the most clinically significant signal.

Gastrointestinal. Nausea and vomiting are the most frequently reported acute symptoms. Abdominal discomfort and bloating may follow. These effects are self-limiting and typically resolve within 12 to 24 hours.

Visual disturbances. The clomiphene citrate FDA label specifically warns about visual symptoms including blurred vision, scotomata (blind spots), flashes, and floaters 3. In a pooled analysis of clomiphene-treated patients, visual complaints occurred in approximately 1.5% at therapeutic doses 5. At supratherapeutic doses, incidence rises. The FDA label states: "Visual symptoms appear to be dose-related, increasing in incidence with increasing total dose or duration of therapy, and generally disappear within a few days or weeks after clomiphene citrate is discontinued."

Vasomotor symptoms. Hot flashes and flushing result from acute estrogen receptor antagonism in thermoregulatory centers. These are uncomfortable but not dangerous.

Hormonal disruption with sustained overdosing. Repeated supratherapeutic dosing over days to weeks can produce supraphysiologic testosterone and suppressed estradiol. Headaches, mood swings, irritability, and decreased libido (paradoxically, from estrogen depletion) may develop. A 2020 review in the Journal of Clinical Endocrinology & Metabolism noted that excessive SERM use in men can drive estradiol below 10 pg/mL, producing symptoms that mimic aromatase inhibitor toxicity 6.

What is NOT expected. Cardiac arrhythmia, seizure, respiratory depression, and loss of consciousness have not been reported with clomiphene-class SERM overdose. The drug does not cause CNS depression or respiratory failure at any documented dose.

Step-by-Step Management of Enclomiphene Overdose

There is no antidote for enclomiphene citrate. Management is supportive and symptom-directed. The following protocol applies to both single accidental excess doses and sustained supratherapeutic ingestion.

Step 1: Contact Poison Control or emergency services. For any ingestion that exceeds the prescribed dose by more than a single extra tablet, call the American Association of Poison Control Centers at 1-800-222-1222. If the patient has visual symptoms, altered mental status, or severe vomiting, go to the emergency department.

Step 2: Discontinue the drug. Stop all enclomiphene dosing until symptoms resolve and a clinician reassesses. The drug's 10-hour elimination half-life means plasma levels will decline substantially within 24 to 48 hours 7. This is a meaningful advantage over racemic clomiphene, where the zuclomiphene (cis) isomer persists with a half-life exceeding 30 days.

Step 3: Gastrointestinal decontamination. Activated charcoal (1 g/kg, maximum 50 g) may be considered if the patient presents within one hour of a large ingestion, per American Academy of Clinical Toxicology guidelines 8. Gastric lavage is not recommended for SERM overdose. Induced vomiting with ipecac is no longer advised for any overdose scenario per current toxicology consensus.

Step 4: Monitor visual function. Any patient reporting blurred vision, scotomata, or light sensitivity after excess enclomiphene should receive a formal ophthalmologic examination. The clomiphene citrate label warns that "prolongation of visual symptoms following discontinuation may occur in rare instances" 3. Retinal examination and visual field testing can rule out the rare but documented occurrence of SERM-associated retinal toxicity.

Step 5: Laboratory assessment. For cases involving sustained overdosing or ingestion of large quantities, obtain serum total testosterone, estradiol, LH, FSH, and a comprehensive metabolic panel. Markedly elevated LH (above 20 IU/L) and suppressed estradiol (below 10 pg/mL) confirm excessive SERM activity and help guide the timeline for drug rechallenge.

Step 6: Supportive care. IV fluids for dehydration from vomiting. Antiemetics (ondansetron 4 mg IV/PO) as needed. Reassurance and observation for 4 to 6 hours in the emergency setting for symptomatic patients.

Enclomiphene vs. Racemic Clomiphene: Why the Isomer Distinction Matters in Overdose

This is not an academic footnote. The difference between enclomiphene and racemic clomiphene citrate directly affects overdose prognosis and duration of toxicity.

Racemic clomiphene citrate (brand name Clomid) contains approximately 62% enclomiphene (trans-isomer) and 38% zuclomiphene (cis-isomer). Enclomiphene is the therapeutically active component that drives GnRH release. Zuclomiphene is a weak estrogen agonist with an extraordinarily long half-life, estimated between 30 and 43 days 7. After overdose with racemic clomiphene, zuclomiphene accumulates and can produce prolonged estrogenic and visual side effects lasting weeks to months.

Pure enclomiphene lacks the zuclomiphene isomer entirely. Its shorter half-life (approximately 10 hours) means that after discontinuation, drug levels fall below clinically active thresholds within 2 to 3 days. Dr. Ronald Swerdloff, Chief of the Division of Endocrinology at Harbor-UCLA Medical Center, has noted regarding clomiphene's isomer composition: "The long-lived zuclomiphene isomer is responsible for many of the unwanted estrogenic effects seen with chronic clomiphene use, including visual symptoms that can persist long after the drug is stopped" 9.

For the patient who has accidentally taken excess enclomiphene (not racemic clomiphene), this pharmacokinetic profile is reassuring. The window of potential toxicity is measured in days rather than weeks.

Risk Factors That May Worsen Outcomes After Excess Dosing

Not all patients face the same risk from an accidental excess dose. Several factors modulate vulnerability.

Concurrent aromatase inhibitor use. Some men on testosterone optimization protocols take anastrozole alongside enclomiphene. An excess dose of enclomiphene in this context produces additive estrogen suppression. Estradiol levels can crash to undetectable levels, producing joint pain, bone density concerns with chronic use, and severe mood disturbance. The Endocrine Society has cautioned against routine aromatase inhibitor co-prescription with SERMs due to this risk 2.

Pre-existing visual conditions. Patients with a history of retinal disease, cataracts, or optic neuropathy have a lower threshold for SERM-associated visual toxicity. The FDA label for clomiphene specifically contraindicates use in patients with "liver disease or a history of liver dysfunction" and advises caution in those with visual disturbances of any etiology 3.

Hepatic impairment. Enclomiphene is hepatically metabolized. Reduced clearance in patients with liver disease could prolong drug exposure after an overdose. Liver function testing is warranted in any overdose patient with known hepatic compromise.

Polypharmacy. Concurrent use of other medications that affect the hypothalamic-pituitary-gonadal axis (testosterone, hCG, GnRH analogues) can produce unpredictable hormonal shifts when combined with excess SERM exposure.

Preventing Accidental Excess Doses

Most accidental overdoses occur through simple medication errors. Dose confusion is common with compounded enclomiphene because capsule strengths vary between pharmacies (6.25 mg, 12.5 mg, 25 mg, and 50 mg formulations all exist). A patient switching pharmacies might take a 50 mg capsule believing it is 12.5 mg.

Practical prevention strategies include verifying capsule strength with each new fill, using a pill organizer to prevent double-dosing, setting a phone alarm for the same time daily, and never adjusting dose without prescriber guidance. The American Association of Poison Control Centers reported approximately 4,200 calls related to hormone and SERM medication errors in 2022, with the majority involving dose confusion rather than intentional ingestion 10.

If you realize you took a double dose, skip the next scheduled dose. Do not try to "balance out" by halving subsequent doses without medical advice. One extra dose at 12.5 or 25 mg is very unlikely to cause any symptoms at all in an otherwise healthy adult male.

When to Seek Emergency Care vs. When to Monitor at Home

A single extra dose (bringing daily intake to 25 to 50 mg total) in a healthy adult typically requires only home observation. Skip the next dose. Watch for visual changes over the following 24 hours.

Emergency evaluation is appropriate when the ingested amount exceeds 100 mg in a single episode, when any visual symptoms develop (blurred vision, flashes, blind spots), when the patient has severe or persistent vomiting, when a child or adolescent has ingested any amount, or when the patient has pre-existing liver disease or is taking concurrent medications affecting the HPG axis.

The Endocrine Society's 2018 guideline emphasizes that SERMs should only be prescribed by clinicians experienced in male endocrinology, and that patients should be educated on adverse effect recognition at the time of prescribing 2. Dr. Shalender Bhasin, the guideline's lead author and Professor of Medicine at Harvard Medical School, stated: "The decision to use a SERM off-label for male hypogonadism must include a thorough discussion of the benefit-risk ratio, including what to do in case of inadvertent excess dosing" 2.

Long-Term Considerations After an Overdose Event

A single accidental excess dose does not typically warrant any change in long-term treatment plan. Resume the prescribed dose after skipping one dose, and inform your prescriber at the next visit.

Sustained supratherapeutic dosing (multiple days at elevated doses) may require a washout period before restarting. Check serum estradiol, total testosterone, and LH/FSH at 1 week and 4 weeks post-discontinuation. If estradiol remains suppressed below 15 pg/mL at 4 weeks, consider whether the patient was actually taking racemic clomiphene (with its long-lived zuclomiphene isomer) rather than pure enclomiphene. Compounding pharmacy verification of product identity is reasonable in this scenario.

Bone mineral density evaluation with DEXA scan is appropriate only if the patient experienced prolonged estradiol suppression (below 10 pg/mL for more than 8 weeks), as estrogen is required for bone maintenance in men. The relationship between estradiol and bone health in men was established by Finkelstein et al. in a landmark New England Journal of Medicine study (N=400), which demonstrated that estradiol, not testosterone, is the dominant sex steroid regulating bone resorption in men 11.

Enclomiphene citrate carries no known risk of organ damage, carcinogenesis, or irreversible toxicity at any single acute dose reported in the literature. The drug's safety profile in overdose, while not extensively studied in isolation from racemic clomiphene, is consistent with a wide therapeutic index.